Downregulation of TAP1 and TAP2 in early stage breast cancer

TAP1-TAP2 heterodimeric complexes are recognized as the transporter associated with antigen processing of major histocompatibility complex class I peptides for recognition by tumor-specific cytotoxic T lymphocytes. In this study, we investigated the immunohistochemical expression of TAP1 and TAP2 in 160 patients with breast cancer and correlated their expression levels with clinicopathologic parameters. The median age of the patient cohort was 52.5 years (range, 30–86 years). Both TAP1 and TAP2 immunohistochemical expression levels correlated significantly with breast cancer characteristics (P < .001). TAP1 expression levels were low to negative in stage I breast tumors. TAP1 and TAP2 levels were significantly higher in grade 3 tumors than low-grade (grade 1 and 2) tumors. TAP1 and TAP2 expression levels were not significantly different among different levels of HER2-expressing tumors and did not vary by estrogen and progesterone receptor status or patient age. Both TAP1 and TAP2 overexpression in breast cancer might be an indicator of an aggressive breast tumor.

[1]  N. Angelopoulos,et al.  Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer , 2015, Breast Cancer Research and Treatment.

[2]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[3]  F. Mami-Chouaib,et al.  TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor‐specific cytotoxic T lymphocytes , 2013, Annals of the New York Academy of Sciences.

[4]  C. Horbinski,et al.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer , 2012, Cancer Immunology, Immunotherapy.

[5]  P. Validire,et al.  Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL , 2011, The Journal of Immunology.

[6]  T. van Hall,et al.  Strategies to counteract MHC-I defects in tumors. , 2011, Current opinion in immunology.

[7]  R. Ferris,et al.  Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes , 2011, Cancer Immunology, Immunotherapy.

[8]  M. Einstein,et al.  Genetic Variants in TAP Are Associated with High-Grade Cervical Neoplasia , 2009, Clinical Cancer Research.

[9]  J. Tao,et al.  Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity. , 2008, The Journal of investigative dermatology.

[10]  R. Gopaul,et al.  Combining the Antigen Processing Components TAP and Tapasin Elicits Enhanced Tumor-Free Survival , 2008, Clinical Cancer Research.

[11]  Wilfred A. Jefferies,et al.  Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas , 2007, Molecular and Cellular Biology.

[12]  B. Seliger,et al.  Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. , 2007, Vaccine.

[13]  W. Jefferies,et al.  TAP expression reduces IL‐10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma , 2007, International journal of cancer.

[14]  R. Tampé,et al.  Modulation of the antigen transport machinery TAP by friends and enemies , 2006, FEBS letters.

[15]  W. Jefferies,et al.  Using the TAP Component of the Antigen-Processing Machinery as a Molecular Adjuvant , 2005, PLoS pathogens.

[16]  B. Seliger,et al.  Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. , 2005, Cancer research.

[17]  Ronald Simon,et al.  Tissue microarrays for early target evaluation. , 2004, Drug discovery today. Technologies.

[18]  Robert Tampé,et al.  The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. , 2004, Physiology.

[19]  M. van de Rijn,et al.  Applications of microarrays to histopathology , 2004, Histopathology.

[20]  M. Ressing,et al.  Bovine herpesvirus 1 interferes with TAP-dependent peptide transport and intracellular trafficking of MHC class I molecules in human cells , 2003, Archives of Virology.

[21]  S. Ferrone,et al.  A Single-nucleotide Deletion Leads to Rapid Degradation ofTAP-1 mRNA in a Melanoma Cell Line* , 2003, The Journal of Biological Chemistry.

[22]  Anneliese Schimpl,et al.  HIV Type 1 Abrogates TAP-Mediated Transport of Antigenic Peptides Presented by MHC Class I , 2002 .

[23]  M. Matsui,et al.  Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon‐γ , 2002, Journal of gastroenterology and hepatology.

[24]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[25]  Holger Moch,et al.  Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology? , 2001, Advances in anatomic pathology.

[26]  K. Wright,et al.  Loss of Interferon-γ Inducibility of TAP1 and LMP2 in a Renal Cell Carcinoma Cell Line , 2000 .

[27]  G. Blair,et al.  Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins , 2000, Oncogene.

[28]  Wilfred A. Jefferies,et al.  TAP expression provides a general method for improving the recognition of malignant cells in vivo , 2000, Nature Biotechnology.

[29]  S. Hinkley,et al.  An Early Pseudorabies Virus Protein Down-Regulates Porcine MHC Class I Expression by Inhibition of Transporter Associated with Antigen Processing (TAP) , 2000, The Journal of Immunology.

[30]  M. Sy,et al.  Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. , 1998, Cancer research.

[31]  D. Hicklin,et al.  HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. , 1998, Cancer research.

[32]  D. Hicklin,et al.  Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. , 1996, Tissue antigens.

[33]  R. Tampé,et al.  A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer , 1996, Nature Genetics.

[34]  A. Harris,et al.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.

[35]  A. Harris,et al.  Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. , 1995, Cancer research.

[36]  A. Harris,et al.  Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. , 1994, The American journal of pathology.

[37]  C. Meijer,et al.  Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. , 1994, British Journal of Cancer.

[38]  C. Meijer,et al.  Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas , 1994, The Journal of experimental medicine.

[39]  Robert Tampé,et al.  The transporter associated with antigen processing: function and implications in human diseases. , 2002, Physiological reviews.

[40]  O. Kutsch,et al.  HIV type 1 abrogates TAP-mediated transport of antigenic peptides presented by MHC class I. Transporter associated with antigen presentation. , 2002, AIDS research and human retroviruses.

[41]  K. Wright,et al.  Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. , 2000, Cancer research.

[42]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.